Answers are grounded in this paper and cite their sources.
OBJECTIVE: This study aimed to develop and externally validate simple, clinically interpretable scoring systems for predicting 12-month visual outcomes in eyes with branch retinal vein occlusion (BRVO), and to evaluate whether the incorporation of optical coherence tomography (OCT) biomarkers improves prognostic performance. DESIGN: Retrospective, multicenter cohort study. SUBJECTS: This study included 356 treatment-naïve eyes from 356 patients with BRVO-associated macular edema. The development cohort comprised 311 eyes from two institutions, whereas an independent cohort of 45 eyes from a third institution underwent external validation. METHODS: A baseline clinical score, the visual acuity and patient age (VAP), was constructed using baseline logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) and age. The VAP-O is an extended score, incorporating OCT-derived biomarkers reflecting retinal structural integrity, including disorganization of the retinal inner layers, hyperreflective foci count, and ellipsoid zone/external limiting membrane disruption. The discriminative ability of each score for predicting poor visual outcome, defined as a 12-month logMAR BCVA of ≥0.3, was evaluated using receiver operating characteristic (ROC) curve analysis in both cohorts. MAIN OUTCOME MEASURES: Area under the ROC curve (AUC), sensitivity, and specificity. RESULTS: The VAP score in the development cohort demonstrated good discriminative performance for poor visual outcome (AUC: 0.791, 95% confidence interval [CI]: 0.724-0.858), with an optimal cutoff value of ≥2. The VAP-O score demonstrated superior performance (AUC: 0.839, 95% CI: 0.771-0.908), with an optimal cutoff value of ≥4. In the external validation cohort, both scores retained discriminative ability, with an AUC of 0.856 (95% CI: 0.734-0.978) for the VAP score and 0.945 (95% CI: 0.879-1.00) for the VAP-O score. CONCLUSIONS: The VAP score provides a simple and clinically accessible tool for early risk stratification of visual prognosis in BRVO. The incorporation of OCT-derived biomarkers into the VAP-O score further improves discriminative performance. These interpretable scoring systems may support individualized prognostic assessment and clinical decision-making in routine ophthalmic practice.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: